secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-07-22T23:59:59+00:00
Accession:  0001193125-25-162552
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics CEO Eric Shaff resigns; CFO and CLO appointed as Co-CEOs effective Aug 1, 2025
--------------------------------------------------------------------------------

- Eric Shaff resigns as President and CEO effective July 31, 2025; remains on Board as Class I director.
- Marella Thorell (EVP/CFO) and Thomas DesRosier (EVP/CLO) appointed Co-CEOs and Co-Presidents effective Aug 1, 2025.
- Shaff to receive prorated 2025 bonus; Board may accelerate payment if a strategic transaction closes before year-end.
- Thorell and DesRosier each receive $500,000 appointment bonus: one-third on Aug 1, 2025, balance on Jan 1, 2026 subject to retention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525162552/0001193125-25-162552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525162552/d40383d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-162552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer